Improving patients' lives through research

At The Ohio State University Division of Nephrology, our team conducts basic, translational and clinical research for diseases that affect the kidney and the consequences of kidney failure.

Clinical Trials

With over 20 active trials, division scientists in the Nephrology Clinical Trials Unit are investigating the following topics:

Lupus Nephritis/SLE

Study Name: Divine
Title: Dynamic Imaging of Variation in Lupus Nephritis (“DIVINE”)
PI: Brad Rovin, MD
Sponsor: RLITE

Study Name: KZR-616 1/2b
Title: A Phase 1b/2 Study of KZR-616 in Patients with Systemic Lupus Erythematosus with and without Nephritis
PI: Samir Parikh, MD
Sponsor: Kezar

Study Name: BMS1107
Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis
PI: Samir Parikh, MD
Sponsor: Bristol Myers Squibb

Study Name: CFZ533
Title: A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients with moderately active proliferative lupus nephritis
PI: Samir Parikh, MD
Sponsor: Novartis

FSGS

Study Name: ROBSO FSGS
Title: A phase 2, 12-week, adaptive, open label, sequential cohort trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple doses in adult subjects with primary focal segmental glomerulosclerosis (FSGS)-
PI: Isabelle Ayoub, MD
Sponsor: Pfizer

Study Name: Voclosporin FSGS
Title: An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
PI: Samir Parikh, MD
Sponsor: Aurinia

Study Name: Duplex
Title: A Randomized, multicenter, double-blind, parallel, active-control study of the effects of sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary FSGS
PI: Isabelle Ayoub, MD
Sponsor: Retrophin

IGA

Study Name: 021GAN17001
Title: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
PI: Isabelle Ayoub, MD
Sponsor: Retrophin

Study Name: NEF-301 IgA
Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary Iga Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
PI: Isabelle Ayoub, MD
Sponsor: Calliditas

Study Name: OMS721-IgA-001
Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (Artemis-IGAN)
PI: Isabelle Ayoub, MD
Sponsor: Omeros

Diabetic Nephropathy

Study Name: Trident
Title: Transformative Research In Diabetic Nephropathy
PI: Salem Almaani, MBBS
Sponsor: UPenn

C3

Study Name: CL011_168
Title: A Randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and efficacy of Avacopan (CCX168) in patients with C3 Glomerulopthy
PI: Samir Parikh, MD
Sponsor: ChemoCentryx, Inc.

Study Name: Achillion C3
Title: An Open-label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471
PI: Samir Parikh, MD
Sponsor: Achillion

CKD

Study Name: EMPA-KIDNEY
Title: EMPA-KIDNEY: A multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease
PI: Udayan Bhatt, MD
Sponsor: Boehringer Ingelheim

Registry

Study Name: Fabry
Title: Fabry Disease Registry Protocol
PI: Isabelle Ayoub, MD
Sponsor: Genzyme

Study Name: CureGN
Title: Cohort consortium of glomerular disease patients followed prospectively with standardized clinical data and bio specimen collection
PI: Brad Rovin, MD
Sponsor: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Name: LVG Registry
Title: Ohio State Lupus and Vasculitis Registry
PI: Stacy Ardoin, MD
Sponsor: Investigator Initiated

Study Name: ALN-LECT2
Title: A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
PI: Samir Parikh, MD
Sponsor: Alnylam

Membranous

Study Name: REBOOT
Title: Anti-plasma cell antibody (cd38) primary MN
PI: Isabelle Ayoub, MD
Sponsor: ITN

Study Name: MOR202C103MN
Title: A Phase Ib/IIA, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)- M-Place
PI: Isabelle Ayoub, MD
Sponsor: Morphosys

Vasculitis

Study Name: INS1007
Title: Safety and Efficacy of INS1007, in the maintenance of remission in patients with Granulomatosis with Polyangiitis GPA
PI: Salem Almaani, MBBS
Sponsor: INSMED

PKD

Study Name: ADPK
Title: A 52-Week Phase 3, Double-blind, Placebo-Controlled, Randomized Study of the Efficacy and Safety of IP in Subjects with Autosomal Dominant Polycystic Kidney Disease
PI: Rima King, MD
Sponsor: Pharm-Olam

Kidney Stone

Study Name: ALLN-177-302
Title: Reloxaliase (ALLN-177)-142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule or matching placebo capsule
PI: Ganesh Shidham, MD
Sponsor: Allena